Suppr超能文献

不宁腿综合征:治疗面临的挑战

Restless Legs Syndrome: Challenges to Treatment.

作者信息

P Laura M Botta, E Samantha S Anguizola, Castro-Villacañas Andrea, Garcia-Borreguero Diego

机构信息

European Sleep Institute, Luis Pasteur 5607 Vitacura, Santiago, Chile.

European Sleep Institute, Edif. Habitats Plaza, Calle 51, Distr, Panamá.

出版信息

Sleep Med Clin. 2021 Jun;16(2):269-277. doi: 10.1016/j.jsmc.2021.02.003. Epub 2021 Apr 15.

Abstract

For a long time, dopaminergic treatment (DT) was the medication for restless legs syndrome. Although DT is effective and safe over the short-term, complications develop over longer periods, including augmentation, tolerance, and impulse control disorders. Nowadays, it is recommended that first-line treatment should be alpha-2 ligands, which are more effective in the absence of previous DT. As a second-line treatment, opioids, such as oxycodone extended-release with naloxone, are approved in Europe. Brain iron should be monitored before and during treatment and corrected if necessary. Two new promising non-DTs are being developed: perampanel and dipyridamole. More research is needed.

摘要

长期以来,多巴胺能治疗(DT)一直是治疗不宁腿综合征的药物。尽管DT在短期内有效且安全,但长期使用会出现并发症,包括症状加重、耐受性和冲动控制障碍。如今,建议一线治疗应使用α-2配体,在未进行过DT治疗的情况下,α-2配体更有效。作为二线治疗,阿片类药物,如含纳洛酮的缓释羟考酮,在欧洲已获批准。治疗前和治疗期间应监测脑铁水平,必要时进行纠正。两种有前景的新型非DT药物正在研发中:吡仑帕奈和双嘧达莫。还需要更多的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验